Accès ouvert
2025
article
OpenAlex
Joshua M. Venegas, Noah Lee Ahmad Nawabi, Aaron L. Miller, Tiffany R. Baker et autres
BACKGROUND: Hemangioblastoma is a slow-growing vascular tumor commonly found in the posterior fossa. It is associated with von Hippel-Lindau disease, yet most cases arise sporadically. Resection and belzutifan are highly effective in the treatment of hemangioblastoma. Rarely, leptomeningeal dissemination may occur months …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Thomas Eckert, Chase M. Walton, Marcus G. Bell, Coulter N. Small et autres
Background: Glioblastoma (GBM) remains the most aggressive primary brain tumor with limited treatment options. The immunosuppressive tumor microenvironment (TME), largely shaped by tumor-associated macrophages (TAMs), represents a significant barrier to effective immunotherapy. Objective: This review aims to explore the role of TAMs …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Thomas Eckert, M. S. Zobaer, Jessie Boulos, Angela A. Alexander-Bryant et autres
BACKGROUND: Glioblastoma (GBM) is the most common primary malignant brain tumor, with fewer than 5% of patients surviving five years after diagnosis. The introduction of immune checkpoint inhibitors (ICIs), followed by chimeric antigen receptor (CAR) T-cell therapy, marked major advancements in oncology. …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Noah L. A. Nawabi, Brian Fabian Saway, Rohan Jha, Matheus Prado Pereira et autres
Background: The National Institute of Health (NIH) provides a sizable annual budget toward brain tumor research. However, funding allocation for specific pathologies remains poorly described. We aimed to characterize the current landscape of NIH funding toward brain tumors as a function of …
us
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Patrick Yung Wen, Jonathan T. Yang, Brandon S. Imber, J. Drappatz et autres
Abstract BACKGROUND Glioblastoma is an aggressive cancer; intensity-modulated radiation therapy (IMRT) with concomitant and adjuvant temozolomide is the first-line standard of care. AZD1390, an ataxia telangiectasia mutated kinase inhibitor, aims to augment the efficacy of IMRT without exacerbating neurotoxicity. AZD1390 is optimized …
us, gb, jp, pl, kr
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Mahnoor Islam, Abhay K. Varma, Charlotte Rivers, William Godwin et autres
Abstract Cesium-131 brachytherapy (GammaTileTM) is a relatively new form of surgically targeted radiation therapy for recurrent glioblastoma. While seed migration is a well-documented complication of solid tumor brachytherapy, it has not been reported in the treatment of glioblastoma. Here, we describe a …
us
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Ashlee R. Loughan, Autumn M. Lanoye, Kelcie D. Willis, Amber Fox et autres
Abstract BACKGROUND Sleep disturbance is commonly endorsed by individuals diagnosed with primary brain tumor (PBT), yet few providers in neuro-oncology assess for sleep disturbance, and even less recommend the gold standard treatment for insomnia: Cognitive Behavioral Therapy for Insomnia (CBT-I). In our …
us
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Arabinda Das, Alicia Marie Zukas, Jaime L. Martínez Santos, Heather R Stephens et autres
Abstract BACKGROUND Human glioblastoma (GBM), especially those exhibiting anti-VEGF resistance, overexpress the carbohydrate-binding protein galectin-1 (Gal-1). To develop novel anti-GBM approaches, we developed Gal-1 targeted CAR-T cells to investigate potential antitumor effect with in vitro and ex vivo slice culture models. METHODS …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
J.T. Yang, Ping Wen, B.S. Imber, Jan Drappatz et autres
us, gb, jp, pl
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Arabinda Das, Daniel G. McDonald, Milad Yazdani, Cynthia A. Welsh et autres
Abstract The prognosis of glioblastoma (GBM) remains poor despite multiple attempts over the years to develop better treatment options for patients with this disease. Various challenges include an immunosuppressive tumor microenvironment, poor knowledge of the neuroimmune system, and the presence of the …
us
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Arabinda Das, Heather R Stephens, Joe Mark, Jeff Garrison et autres
Abstract BACKGROUND Most glioblastoma (GBM) patients experience tumor recurrence following standard-of-care treatment which includes tumor resection, radiation, and chemotherapy with concomitant and adjuvant temozolomide. Currently, no murine surgical GBM resection models to evaluate novel therapies exist and understanding of postsurgical tumor microenvironment …
us
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Autumn M. Lanoye, Amber Fox, Kelcie D. Willis, Alicia Marie Zukas et autres
Abstract BACKGROUND Sleep disturbance is among the most common complaints endorsed by patients with a brain tumor diagnosis, yet the delivery of behavioral insomnia treatment is not standard practice in neuro-oncology. Our pilot trial of a 6-session group-based telehealth CBT-I program among …
us
(code pays fourni par la source)